{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"groups":[{"description":"Participants with Hodgkin's lymphoma","id":"OG000","title":"Cohort 2"},{"description":"Participants with non-Hodgkin's lymphoma","id":"OG001","title":"Cohort 4"}],"paramType":"NUMBER","populationDescription":"Included safety-evaluable population, defined as patients who received any amount of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)","title":"Percentage of Participants With an Objective Response (CR or PR) as Determined by the Investigator Using Revised Response Criteria for Malignant Lymphoma for Participants With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma","type":"PRIMARY","unitOfMeasure":"Percentage"}